hrp0082fc9.6 | Beta cells | ESPE2014

Sulfonylurea Therapy Corrects Hypotonia, Attention Deficits, Improves Complex Neuropsychological Functions and Motricity in Patients with Neonatal Diabetes Secondary to Mutation in Potassium Channel Subunits, Through a CNS Effect

Beltrand Jacques , Vaivre-Douvret Laurence , Busiah Kanetee , Fournier Emmanuel , Boddaert Nathalie , Vera Myriam , Bahi-Buisson Nadia , Bui-Quoc Emmanuel , Ingster-Moati Isabelle , Flechtner Isabelle , Simon Albane , Scharfmann Raphael , Cave Helene , Elie Caroline , Polak Michel

Background: Sulfonylurea therapy (SU) allows a better metabolic control than insulin in patients with neonatal diabetes secondary to mutation in potassium channel subunits (ND-K). Most of these patients have neurological and neuromotor developmental impairments whose changes under SU has not been studied in a systematic and prospective way in a large cohort.Objective and Hypotheses: To demonstrate the beneficial effect of SU on neuropsychological functio...

hrp0082p1-d1-145 | Growth | ESPE2014

Genotype–Phenotype Relationship in Patients with SHOX Region Rearrangements Detected by MLPA in the French Population

Auger Julie , Baptiste Amandine , Thierry Gaelle , Costa Jean-Marc , Amouyal Melanie , Kottler Marie-Laure , Touraine Renaud , Lebrun Marine , Leheup Bruno , Schmitt Sebastien , Cormier-Daire Valerie , De Roux Nicolas , Elie Caroline , Bonnefont Jean-Paul

Background: SHOX and enhancer regions on PAR1 disorders have variable phenotypic consequences such as idiopathic short stature (ISS) and Leri-Weill Dyschondrosteosis (LWD).Objective and hypotheses: The aim of this observational multicentric study was to describe phenotypes and genotypes of a large population with mutation on SHOX and adjacent regions and to identify a possible phenotype–genotype correlation.M...

hrp0082p2-d3-310 | Bone (2) | ESPE2014

Outcomes of Vitamin D Analogues and Phosphate Supplements in Patients With Hereditary Hypophosphatemic Rickets , Comparison With Non-Treated Patients

Boros Emese , Rothenbuhler Anya , Heinrichs Claudine , Brachet Cecile , Esterle Laure , Kamenicky Peter , Harvengt Pol , Brailly-Tabard Sylvie , Haidar Hazar , Gaucher Celine , Silve Caroline , Gossiome Charles , Wicart Philippe , Duplan Martin Biosse , Courson Frederic , Chaussain Catherine , Linglart Agnes

Background: Hereditary Hypophosphatemic Rickets (HHR) is caused by persistently elevated FGF23 resulting in renal phosphate wasting and decreased 25 vitamin D hydroxylation. Treatment with vitamin D analogues (VDA) has been added to phosphate supplements in the late seventies.Objective and hypotheses: Our objective was to evaluate the outcomes of VDA and phosphate supplements in adult patients with HHR in comparison with patients who did not receive VDA ...

hrp0082p2-d3-483 | Hypoglycaemia | ESPE2014

Neurodevelopmental Outcomes in Early and Late Presenting Congenital Hyperinsulinism

Mohamed Zainaba , Nicholson Jacqueline , Zamir Imran , Butler Thomas , Rigby Lindsey , Bowden Louise , Murray Philip , Steele Caroline , Rao Padidela Raja Narender , Patel Leena , Cosgrove Karen , Clayton Peter , Dunne Mark , Banerjee Indraneel

Background: Hypoglycaemia due to congenital hyperinsulinism (CHI) usually presents early (E-CHI) in the neonatal period, but late presentation (age >1 month) (L-CHI) also occurs. Adverse neurodevelopment is well recognised in both early and late CHI, but differences between both groups are not known.Objective and hypotheses: We examined a cohort of children with E-CHI and L-CHI to test neurodevelopmental outcomes in mid-childhood.<p class="abstex...

hrp0082p3-d3-653 | Autoimmune Endocrine Disease | ESPE2014

Late Endocrine Effects in Children and Adolescentes Submitted to Allogenic Bone Marrow Transplantation

Kuperman Hilton , Pinchiari Lilian Argentino , Medrado Caroline Kupsch , Battistin Claudilene , Manna Thais Della , Dichtchkenian Vae , de Menezes Filho Hamilton Cabral , Steinmetz Leandra , Cominato Louise , Fernandes Juliana Folloni , Cristofani Lilian Maria , Filho Vicente Odone , Damiani Durval

Background: Pediatric bone marrow transplantation (BMT) can lead to endocrine dysfunctions due to common pre-operative regimens involving chemo and radiotherapy.Objective and hypotheses: To evaluate the prevalence an time-of-onset of endocrine dysfunctions after BMT in children and adolescents.Method: A retrospective cohort-study design was performed. The inclusion criteria were: <18 years of age at the time of their allogenic ...

hrp0094fc10.5 | Thyroid | ESPE2021

Adjuvant Rituximab – exploratory trial in young people with Graves’ disease

Cheetham Tim , Cole Michael , Abinun Mario , Alalhabadia Amit , Barratt Tim , Kirk Jeremy , Davies Justin , Dimitri Paul , Drake Amanda , Murray Robert , Steele Caroline , Zammitt Nicola , Carnell Sonya , Howell Denise , Prichard Jonathan , Watson Gillian , Matthews John , Pearce Simon ,

Objective: Remission rates in young people with Graves’ hyperthyroidism are 25% or less after a 2-yr course of thionamide antithyroid drug (ATD). Immunomodulatory agents could potentially improve outcome by facilitating immune tolerance. We wanted to explore whether rituximab, a B lymphocyte depleting agent, would increase remission rates when administered with a short course of ATD.Design: This was an investigator-...

hrp0097t8 | Section | ESPE2023

Design and Objectives of the Acorn Study: A Non-Interventional Study Evaluating Long-term Safety in Achondroplasia Patients Treated with Vosoritide

M Pimenta Jeanne , Cohen Shelda , Mukherjee Swati , Fettes Fiona , Jayaram Kala , Lausch Ekkehart , Mallya Usha G. , Min Yang , Caroline Huber , Cala Mary Lynn , Ali Greatsinger , Jeremy Pomeroy , Haqq Andrea M.

Introduction: Achondroplasia is caused by a pathogenic mutation in the FGFR3 gene, leading to impaired endochondral bone growth and multiple medical complications. Vosoritide, a modified recombinant human C-type natriuretic peptide (rhCNP), was approved by the European Medicines Agency (EMA) in August 2021 for treating genetically confirmed achondroplasia in patients aged ≥2 years until closure of epiphyses. Acorn is the first treatment-based registry for a...

hrp0089p3-p182 | Fetal, Neonatal Endocrinology and Metabolism P3 | ESPE2018

Dumping Syndrome in a Neonate with Esophagical Atresia Surgery

Gonzalez Angelica , Jaramillo Carolina , Espejo Jennyfer Monroy

Introduction: Dumping Syndrome (DS) has been recognized as a major complication of Nissen fundoplication in young children. Althougth other causes have been recognized. We describe a children with esophageal atresia who presented with late DS caused by a surgical complication, Dumping and Horner syndrome were diagnosticated after his surgery.Case description: A male newborn with prenatal diagnosis of right Aortic Arch was born by vaginal delivery, radiol...

hrp0086p1-p806 | Syndromes: Mechanisms and Management P1 | ESPE2016

Metabolic Health and Safety of GH-Treatment in Silver-Russell Syndrome

Smeets Carolina , Renes Judith , Hokken-Koelega Anita

Background: Silver-Russell syndrome (SRS) is characterized by small for gestational age (SGA) birth, severe short stature and variable dysmorphic features. Children born SGA are at increased risk to develop adult-onset disease at a relatively young age. Growth hormone (GH)-treatment is a registered growth-promoting therapy for short children born SGA, including SRS. Data on metabolic health and long-term safety of GH-treatment in SRS are limited.Objectiv...

hrp0086p2-p943 | Thyroid P2 | ESPE2016

Thyrotoxic Periodic Paralysis, an Under-Recognized Condition

Nip Siu Ying , Di Blasi Carolina

Background: Thyrotoxic periodic paralysis (TPP) is a rare clinical manifestation of hyperthyroidism, commonly seen in Asian males. Patients often present with sudden onset muscle weakness associated with severe hypokalemia.Case presentation: A 16-year-old Filipino male presented with acute onset bilateral lower extremities weakness. He woke up at night but was unable to move his legs. He denied any recent viral infections, ingestion of canned food or his...